Derek Meisner was Appointed as General Counsel at X4-Pharmaceuticals

Date of management change: November 04, 2019 

What Happened?

Cambridge, -based X4-Pharmaceuticals Appointed Derek Meisner as General Counsel

 

About the Company

X4 Pharmaceuticals (Nasdaq: XFOR) is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. The company`s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4`s most advanced product candidate, mavorixafor (X4P-001), is in a global Phase 3 pivotal trial in patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease, and is currently also under investigation in combination with axitinib in the Phase 2a portion of an open-label Phase 1/2 clinical trial in clear cell renal cell carcinoma (ccRCC). X4 is also planning to commence clinical trials of mavorixafor in Severe Congenital Neutropenia (SCN) and Waldenström`s macroglobulinemia (WM) in 2019. The company was founded and is led by a team with extensive biopharmaceutical product development and commercialization expertise and is committed to advancing the development of innovative medicines on behalf of patients with limited treatment options. X4 is a global company that is headquartered in Cambridge, Massachusetts with research offices based in Vienna, Austria.

 

About the Person

Derek Meisner is Senior Vice President and General Counsel at X4 Pharmaceuticals. Previously, Derek held various senior legal leadership roles in the industry.

 

Info Source

News

 
 

Other IT executives who recently changed jobs as well: Cohen Paul, Haynes Roy, Mercier Monique, Rundle Kate, Witty Peter, Sassalos Paul, Dipietro Louis, Williams Vanessa, Berner Kristy, Ellis Terry, Witmer Valerie

You can find the full directory of IT executives here.

How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.